Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
NonrulemakingNoticeFDA_FRDOC_0001-14290
Comments
0
Awaiting comments
Deadline
--
Net supportiSupport minus oppose · campaigns included
—
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Jun 22, 2026
- Comment period
- Jun 22, 2026 – ?
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-12367
Analysis
Overview
No comments yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
No comments match.